Literature DB >> 7515559

Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry.

T van Agthoven1, M Timmermans, J A Foekens, L C Dorssers, S C Henzen-Logmans.   

Abstract

Distribution of estrogen (ER), progesterone (PR) receptors, and epidermal growth factor (EGF) receptors was assayed by dual staining immunohistochemistry on 28 selected cytosolic ER-positive breast carcinomas and 22 nonmalignant breast tissues. ER-positive tumor cells were detected in 26 (93%) and EGF receptor positive tumor cells were detected in 7 (25%) carcinomas. In five tumors both ER and EGF receptors were detected but localized in distinct tumor cells. Only in one case of ductal carcinoma in situ co-expression was observed in a subset of tumor cells. In contrast, simultaneous expression of ER/PR and EGF receptors was observed in non-neoplastic ductal remnants in the majority of the carcinomas and the fibroadenomas. In addition, double-positive cells were occasionally detected in luminal epithelial cells of normal breast tissue and mastopathies. This study shows that ER/PR and EGF receptors in breast tumor cells are inversely related at the single cell level. However, demonstration of ER/PR and EGF receptors in individual normal luminal cells shows that expression is not mutually exclusive.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515559      PMCID: PMC1887470     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

Review 1.  Antireceptor antibodies in the study of EGF-receptor interaction.

Authors:  L H Defize; C L Mummery; W H Moolenaar; S W de Laat
Journal:  Cell Differ       Date:  1987-03

2.  Special report. Steriod receptors in breast cancer.

Authors:  E R DeSombre; P P Carbone; E V Jensen; W L McGuire; S A Wells; J L Wittliff; M B Lipsett
Journal:  N Engl J Med       Date:  1979-11-01       Impact factor: 91.245

3.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.

Authors:  A Ullrich; L Coussens; J S Hayflick; T J Dull; A Gray; A W Tam; J Lee; Y Yarden; T A Libermann; J Schlessinger
Journal:  Nature       Date:  1984 May 31-Jun 6       Impact factor: 49.962

Review 4.  Mechanisms of hormone resistance in breast cancer.

Authors:  K B Horwitz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

5.  Hormone dependency of breast cancer.

Authors:  E V Jensen
Journal:  Cancer       Date:  1981-05-15       Impact factor: 6.860

6.  Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer.

Authors:  J R Sainsbury; J R Farndon; G K Needham; A J Malcolm; A L Harris
Journal:  Lancet       Date:  1987-06-20       Impact factor: 79.321

7.  Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.

Authors:  B Fisher; C Redmond; A Brown; D L Wickerham; N Wolmark; J Allegra; G Escher; M Lippman; E Savlov; J Wittliff
Journal:  J Clin Oncol       Date:  1983-04       Impact factor: 44.544

Review 8.  William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

Authors:  R J King
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Role of steroid hormone receptors as prognostic factors in primary breast cancer.

Authors:  W L McGuire; G M Clark; L G Dressler; M A Owens
Journal:  NCI Monogr       Date:  1986

10.  Immunochemical studies of estrogen receptors.

Authors:  G L Greene; N B Sobel; W J King; E V Jensen
Journal:  J Steroid Biochem       Date:  1984-01       Impact factor: 4.292

View more
  19 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

Review 3.  Intrinsic and Extrinsic Factors Governing the Transcriptional Regulation of ESR1.

Authors:  David K Lung; Rebecca M Reese; Elaine T Alarid
Journal:  Horm Cancer       Date:  2020-06-26       Impact factor: 3.869

4.  Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas.

Authors:  S La Rosa; F Sessa; L Colombo; M G Tibiletti; D Furlan; C Capella
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

Review 5.  Tamoxifen resistance in breast cancer: elucidating mechanisms.

Authors:  L C Dorssers; S Van der Flier; A Brinkman; T van Agthoven; J Veldscholte; E M Berns; J G Klijn; L V Beex; J A Foekens
Journal:  Drugs       Date:  2001       Impact factor: 9.546

6.  Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors.

Authors:  Angela Brodie; Gauri Sabnis
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

Review 7.  Estrogen receptor variants.

Authors:  T A Hopp; S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 8.  Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland.

Authors:  M De Bortoli; C Dati
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 9.  Chemoprevention of breast cancer: implications for postmenopausal women.

Authors:  Carol J Fabian; Bruce F Kimler
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 10.  ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers.

Authors:  Joeli A Brinkman; Dorraya El-Ashry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-03-05       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.